IvanT retweetledi

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us.
Read our opinion piece in @JCO_ASCO
ascopubs.org/doi/full/10.12…

English

























